Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TRS01 eye · 2 trials · 2 indications
Number of patients experiencing Adverse Events during the study
| Arm | Type | Description |
|---|---|---|
| TRS01 low dose | EXPERIMENTAL | - |
| TRS01 high dose | EXPERIMENTAL | - |
| TRS01 medium dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TRS01 eye drops | DRUG | Dosed four times a day (QID) |
| Placebo eye drops | DRUG | Dosed QID |
Inclusion Criteria: * 18 years of age or older * Able to provide informed consent, follow instructions and complete all required study visits for the duration of the study. * Diagnosed with active non-infectious anterior uveitis requiring an increase or initiation of topical steroids for management...
TRS01 eye is an investigational small molecule eye drop being developed for non-infectious anterior uveitis and post-surgical ocular inflammation. It is currently in Phase 1 clinical development and has not been approved by the FDA.
TRS01 eye is a small molecule, but its specific molecular target has not been disclosed. It is being studied for its effects on ocular inflammation in conditions like non-infectious anterior uveitis and post-surgical ocular inflammation.
TRS01 eye is being developed by Tarsier Pharma Ltd., a biopharmaceutical company. The company's ticker symbol is TARX.
TRS01 eye is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed.
TRS01 eye has been studied in two completed Phase 1 trials: NCT04222712 for active non-infectious anterior uveitis and NCT04222725 for post-surgical ocular inflammation. Both trials were conducted in the United States.
TRS01 eye is the eye drop formulation of TRS01, a small molecule being developed by Tarsier Pharma Ltd. The drug is referred to as TRS01 eye in clinical trials for ocular conditions.